All In Biotech

Drug Trial Radar · NCT05727878

Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

A Study to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

103

Actual

Start

Feb 7, 2023

Primary completion

Sep 29, 2025

Study completion Oct 19, 2025

Sponsor

Lead sponsor
Combangio, IncIndustry
Sponsor type
Industry
Collaborators
Kala Pharmaceuticals, Inc.
First posted
Feb 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.

Conditions

  • Persistent Corneal Epithelial Defect

Interventions

  • KPI-012Drug

    KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells

  • KPI-012 VehicleDrug

    KPI-012 formulation with no active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response statusTime frame: Day 56

Locations

46 sites in 3 countries. Site status is shown where the registry gives one.

  • Principal Investigator

    Dothan, Alabama

  • Principal Investigator

    Irvine, California

  • Principal Investigator

    La Jolla, California

  • Principal Investigator

    Loma Linda, California

  • Principal Investigator

    Los Angeles, California

  • Principal Investigator

    Los Angeles, California

  • Principal Investigator

    Pasadena, California

  • Principal Investigator

    Rancho Cordova, California

  • Principal Investigator

    Aurora, Colorado

  • Principal Investigator

    Fort Collins, Colorado

  • Principal Investigator

    Littleton, Colorado

  • Principal Investigator

    Miami, Florida

  • Principal Investigator

    Miami, Florida

  • Principal Investigator

    Orange City, Florida

  • Principal Investigator

    Atlanta, Georgia

  • Principal Investigator

    Carmel, Indiana

  • Principal Investigator

    Indianapolis, Indiana

  • Principal Investigator

    Louisville, Kentucky

  • Principal Investigator

    Boston, Massachusetts

  • Principal Investigator

    Boston, Massachusetts

  • Principal Investigator

    Chesterfield, Missouri

  • Principal Investigator

    Kansas City, Missouri

  • Principal Investigator

    Kansas City, Missouri

  • Principal Investigator

    St Louis, Missouri

  • Principal Investigator

    Palisades Park, New Jersey

  • Principal Investigator

    New York, New York

  • Principal Investigator

    Rockville Centre, New York

  • Principal investigator

    Durham, North Carolina

  • Principal Investigator

    Garner, North Carolina

  • Principal Investigator

    Powell, Ohio

  • Principal Investigator

    Philadelphia, Pennsylvania

  • Principal Investigator

    Pittsburgh, Pennsylvania

  • Principal Investigator

    Rapid City, South Dakota

  • Principal Investigator

    Memphis, Tennessee

  • Principal Investigator

    Nashville, Tennessee

  • Principal Investigator

    Austin, Texas

  • Principal Investigator

    Austin, Texas

  • Principal Investigator

    Houston, Texas

  • Principal Investigator

    San Antonio, Texas

  • Principal Investigator

    Norfolk, Virginia

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.